214 related articles for article (PubMed ID: 36871910)
1. Association analysis of gut microbiota and efficacy of SSRIs antidepressants in patients with major depressive disorder.
Gao M; Tu H; Liu P; Zhang Y; Zhang R; Jing L; Zhang K
J Affect Disord; 2023 Jun; 330():40-47. PubMed ID: 36871910
[TBL] [Abstract][Full Text] [Related]
2. Exploring the human gut microbiota targets in relation to the use of contemporary antidepressants.
Lin SK; Chen HC; Chen CH; Chen IM; Lu ML; Hsu CD; Chiu YH; Wang TY; Chen HM; Chung YE; Kuo PH
J Affect Disord; 2024 Jan; 344():473-484. PubMed ID: 37820962
[TBL] [Abstract][Full Text] [Related]
3. Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials.
Huang KL; Lu WC; Wang YY; Hu GC; Lu CH; Lee WY; Hsu CC
Aust N Z J Psychiatry; 2014 Jul; 48(7):663-71. PubMed ID: 24604920
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of gut microbiota and its correlation with hs-CRP and somatic symptoms in first-episode treatment-naive major depressive disorder.
Liu P; Jing L; Guo F; Xu Y; Cheng J; Liu S; Liu L; Liu Z; Zhang K; Sun N
J Affect Disord; 2024 Jul; 356():664-671. PubMed ID: 38615845
[TBL] [Abstract][Full Text] [Related]
5. Differences in bacterial taxa between treatment-naive patients with major depressive disorder and non-affected controls may be related to a proinflammatory profile.
Knudsen JK; Bundgaard-Nielsen C; Leutscher P; Hjerrild S; Nielsen RE; Sørensen S
BMC Psychiatry; 2024 Jan; 24(1):84. PubMed ID: 38297265
[TBL] [Abstract][Full Text] [Related]
6. A review of the antimicrobial side of antidepressants and its putative implications on the gut microbiome.
McGovern AS; Hamlin AS; Winter G
Aust N Z J Psychiatry; 2019 Dec; 53(12):1151-1166. PubMed ID: 31558039
[TBL] [Abstract][Full Text] [Related]
7. The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries.
Fugger G; Bartova L; Fabbri C; Fanelli G; Dold M; Swoboda MMM; Kautzky A; Zohar J; Souery D; Mendlewicz J; Montgomery S; Rujescu D; Serretti A; Kasper S
Eur Arch Psychiatry Clin Neurosci; 2022 Jun; 272(4):715-727. PubMed ID: 34989830
[TBL] [Abstract][Full Text] [Related]
8. Gut microbiota and inflammatory factor characteristics in major depressive disorder patients with anorexia.
Guo F; Jing L; Xu Y; Zhang K; Li Y; Sun N; Liu P; Zhang H
BMC Psychiatry; 2024 May; 24(1):334. PubMed ID: 38698338
[TBL] [Abstract][Full Text] [Related]
9. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
Oakes TM; Dellva MA; Waterman K; Greenbaum M; Poppe C; Goldberger C; Ahl J; Perahia DG
Curr Med Res Opin; 2015 Jun; 31(6):1179-89. PubMed ID: 25894953
[TBL] [Abstract][Full Text] [Related]
10. Selective Serotonin Reuptake Inhibitors and Serotonin and Noradrenaline Reuptake Inhibitors Improve Cognitive Function in Partial Responders Depressed Patients: Results from a Prospective Observational Cohort Study.
Castellano S; Ventimiglia A; Salomone S; Ventimiglia A; De Vivo S; Signorelli MS; Bellelli E; Santagati M; Cantarella RA; Fazio E; Aguglia E; Drago F; Di Nuovo S; Caraci F
CNS Neurol Disord Drug Targets; 2016; 15(10):1290-1298. PubMed ID: 27712575
[TBL] [Abstract][Full Text] [Related]
11. EEG microstates as markers of major depressive disorder and predictors of response to SSRIs therapy.
Lei L; Liu Z; Zhang Y; Guo M; Liu P; Hu X; Yang C; Zhang A; Sun N; Wang Y; Zhang K
Prog Neuropsychopharmacol Biol Psychiatry; 2022 Jun; 116():110514. PubMed ID: 35085607
[TBL] [Abstract][Full Text] [Related]
12. The change of gut microbiota in MDD patients under SSRIs treatment.
Shen Y; Yang X; Li G; Gao J; Liang Y
Sci Rep; 2021 Jul; 11(1):14918. PubMed ID: 34290352
[TBL] [Abstract][Full Text] [Related]
13. Antidepressants for the treatment of depression in people with cancer.
Ostuzzi G; Matcham F; Dauchy S; Barbui C; Hotopf M
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011006. PubMed ID: 29683474
[TBL] [Abstract][Full Text] [Related]
14. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review.
Ruhé HG; Huyser J; Swinkels JA; Schene AH
J Clin Psychiatry; 2006 Dec; 67(12):1836-55. PubMed ID: 17194261
[TBL] [Abstract][Full Text] [Related]
15. Agomelatine versus other antidepressive agents for major depression.
Guaiana G; Gupta S; Chiodo D; Davies SJ; Haederle K; Koesters M
Cochrane Database Syst Rev; 2013 Dec; (12):CD008851. PubMed ID: 24343836
[TBL] [Abstract][Full Text] [Related]
16. Long-term management of major depressive disorder: are differences among antidepressant treatments meaningful?
Shelton CI
J Clin Psychiatry; 2004; 65 Suppl 17():29-33. PubMed ID: 15600379
[TBL] [Abstract][Full Text] [Related]
17. Antidepressants for the treatment of depression in people with cancer.
Ostuzzi G; Matcham F; Dauchy S; Barbui C; Hotopf M
Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD011006. PubMed ID: 26029972
[TBL] [Abstract][Full Text] [Related]
18. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
[TBL] [Abstract][Full Text] [Related]
19. [Fluoxetine: an update of its use in major depressive disorder in adults].
Gourion D; Perrin E; Quintin P
Encephale; 2004; 30(4):392-9. PubMed ID: 15597466
[TBL] [Abstract][Full Text] [Related]
20. Vortioxetine: a New Treatment for Major Depressive Disorder.
Connolly KR; Thase ME
Expert Opin Pharmacother; 2016; 17(3):421-31. PubMed ID: 26679430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
